drugset
drugset / Trial / NCT02419820

Dose-escalation, Repeated and Single Oral Dosing Study

NCT02419820 ↗

Phase 1 Terminated 104 enrolled IlDong Pharmaceutical Co Ltd Asan Medical Center · collab
RandomizedParallel-groupQuadruple-blindScreening

Summary

Randomized, Double-blind, Placebo-controlled, Dose-escalation, Repeated and Single Oral Dosing Phase I Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of APD791 (Temanogrel) Co-administered with Aspirin and Clopidogrel.

Timeline

Start
2015-03
Primary completion
2016-04
Completion
2016-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Temanogrel Small molecule 2 mg Oral
Subject Temanogrel Small molecule 5 mg Oral
Subject Temanogrel Small molecule 10 mg Oral
Subject Temanogrel Small molecule 20 mg Oral
Subject Temanogrel Small molecule 40 mg Oral
Subject Temanogrel Small molecule 80 mg Oral
Subject Temanogrel Small molecule 160 mg Oral
Subject Temanogrel Small molecule 240 mg Oral
Subject Temanogrel Small molecule 320 mg Oral
Background Aspirin Small molecule — Oral
Background Clopidogrel Small molecule — Oral

Indications

acute coronary syndrome